Erik Løkkevik

947 total citations
14 papers, 632 citations indexed

About

Erik Løkkevik is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Erik Løkkevik has authored 14 papers receiving a total of 632 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Erik Løkkevik's work include Cancer-related Molecular Pathways (6 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Erik Løkkevik is often cited by papers focused on Cancer-related Molecular Pathways (6 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Treatment and Pharmacology (3 papers). Erik Løkkevik collaborates with scholars based in Norway, United Kingdom and Netherlands. Erik Løkkevik's co-authors include Per Eystein Lønning, Terje Risberg, Alv A. Dahl, Sophie D. Fosså, Anne Marit Mengshoel, Steinar Lundgren, Bjørn Østenstad, Ingvil Mjaaland, Gun Anker and Stian Knappskog and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Erik Løkkevik

14 papers receiving 617 citations

Peers

Erik Løkkevik

ONCOL

GENET

SURGE

Jens Ole Eriksen Denmark

Marco Greco Italy

E Gubała Poland

Michael S. McLemore United States

Fiona E. McRonald United Kingdom

Yasunari Mizumoto Japan

Helen Koutselini Greece

Tülay Canda Türkiye

S A Bartow United States

Sandro Casavilca‐Zambrano Peru

Jens Ole Eriksen Denmark

Erik Løkkevik

189 ×0.5

ONCOL

199 ×1.0

132 ×0.8

117 ×0.9

GENET

36 ×0.4

SURGE

Citations per year, relative to Erik Løkkevik Erik Løkkevik (= 1×) peers Jens Ole Eriksen

Countries citing papers authored by Erik Løkkevik

Since Specialization

Citations

This map shows the geographic impact of Erik Løkkevik's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Erik Løkkevik with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Erik Løkkevik more than expected).

Fields of papers citing papers by Erik Løkkevik

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Erik Løkkevik. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Erik Løkkevik. The network helps show where Erik Løkkevik may publish in the future.

Co-authorship network of co-authors of Erik Løkkevik

This figure shows the co-authorship network connecting the top 25 collaborators of Erik Løkkevik. A scholar is included among the top collaborators of Erik Løkkevik based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Erik Løkkevik. Erik Løkkevik is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Knappskog, Stian, Ranjan Chrisanthar, Stephanie Geisler, et al.. (2015). Concomitant inactivation of the p53‐ and pRB‐ functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. Molecular Oncology. 9(8). 1553–1564. 21 indexed citations

Knappskog, Stian, Liv B. Gansmo, Pål Romundstad, et al.. (2012). MDM2 Promoter SNP344T>A (rs1196333) Status Does Not Affect Cancer Risk. PLoS ONE. 7(4). e36263–e36263. 10 indexed citations

Knappskog, Stian, Ranjan Chrisanthar, Erik Løkkevik, et al.. (2012). Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. Breast Cancer Research. 14(2). R47–R47. 58 indexed citations

Engebraaten, Olav, Hege Edvardsen, Erik Løkkevik, et al.. (2012). Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial. ISRN Oncology. 2012. 1–8. 12 indexed citations

Wist, E., et al.. (2012). Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. Journal of Oncology. 2012. 1–7. 6 indexed citations

Mathiesen, Randi R., Elin Borgen, Anne Renolen, et al.. (2012). Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival. Breast Cancer Research. 14(4). R117–R117. 54 indexed citations

Chrisanthar, Ranjan, Stian Knappskog, Erik Løkkevik, et al.. (2011). Predictive and Prognostic Impact of TP53 Mutations and MDM2 Promoter Genotype in Primary Breast Cancer Patients Treated with Epirubicin or Paclitaxel. PLoS ONE. 6(4). e19249–e19249. 81 indexed citations

Dahl, Alv A., et al.. (2008). Arm and shoulder morbidity in breast cancer patients after breast-conserving therapy versus mastectomy. Acta Oncologica. 47(5). 835–842. 133 indexed citations

Danielsen, Turi, et al.. (2008). Late regional density changes of the lung after radiotherapy for breast cancer. Radiotherapy and Oncology. 90(1). 148–152. 4 indexed citations

10.

Chrisanthar, Ranjan, Stian Knappskog, Erik Løkkevik, et al.. (2008). CHEK2 Mutations Affecting Kinase Activity Together With Mutations in TP53 Indicate a Functional Pathway Associated with Resistance to Epirubicin in Primary Breast Cancer. PLoS ONE. 3(8). e3062–e3062. 75 indexed citations

11.

Geisler, Jürgen, Per Eystein Lønning, Lars Erik Krag, et al.. (2006). Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: A randomised, placebo-controlled study. European Journal of Cancer. 42(17). 2968–2975. 84 indexed citations

12.

Staalesen, Vidar, Stian Knappskog, Ranjan Chrisanthar, et al.. (2006). The Novel p21 Polymorphism p21G251A Is Associated with Locally Advanced Breast Cancer. Clinical Cancer Research. 12(20). 6000–6004. 12 indexed citations

13.

Lønning, Per Eystein, Jürgen Geisler, Lars Erik Krag, et al.. (2006). Vitamin D deficiency: A threat to bone health in breast cancer patients during adjuvant treatment with aromatase inhibitors. Journal of Clinical Oncology. 24(18_suppl). 554–554. 12 indexed citations

14.

Løkkevik, Erik, Eva Skovlund, Jon B. Reitan, Einar Hannisdal, & Gunnar Tanum. (1996). Skin Treatment with Bepanthen Cream Versus No Cream During Radiotherapy: A randomized controlled trial. Acta Oncologica. 35(8). 1021–1026. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact